Li Xie

Baricitinib in Patients with Refractory Rheumatoid Arthritis

Mark C. Genovese, Joel Kremer, Omid Zamani et al. · New England Journal of Medicine · 2016 · 621 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

A Phase II Randomized Study of Subcutaneous Ixekizumab, an Anti–Interleukin‐17 Monoclonal Antibody, in Rheumatoid Arthritis Patients Who Were Naive to Biologic Agents or Had an Inadequate Response to Tumor Necrosis Factor Inhibitors

Mark C. Genovese, Maria Greenwald, Chul‐Soo Cho et al. · Arthritis & Rheumatology · 2014 · 205 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Effects of Teriparatide in Postmenopausal Women with Osteoporosis on Prior Alendronate or Raloxifene: Differences between Stopping and Continuing the Antiresorptive Agent

Felicia Cosman, Robert A. Wermers, Christopher Recknor et al. · The Journal of Clinical Endocrinology & Metabolism · 2009 · 172 citations

Medicine, Pharmacology, Pharmacotherapy +17

Safety and Efficacy of Teriparatide in Elderly Women with Established Osteoporosis: Bone Anabolic Therapy from a Geriatric Perspective

Steven Boonen, Fernando Marín, Dan Mellström et al. · Journal of the American Geriatrics Society · 2006 · 134 citations

Medicine, Geriatric Medicine, Pharmacotherapy +17

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

Josef S Smolen, Joel M. Kremer, C. Gaich et al. · Annals of the Rheumatic Diseases · 2016 · 115 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +17